Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Expected gross proceeds are approximately $350.0 million before underwriting discounts, commissions and other offering expenses.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spyre Therapeutics (SYRE) priced its previously announced underwritten public offering of common stock at $85.00 per share to raise additional capital. The offering comprises 4,117,648 shares, with expected gross proceeds of approximately $350.0 million before underwriting discounts, commissions and other offering expenses. Underwriters have a 30-day option to purchase up to an additional approximately $52.5 million of shares on the same terms.
Spyre expects closing on or about October 7, 2026, subject to customary closing conditions. It intends to fund development across Gastroenterology, Rheumatology and Dermatology, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness, plus a new program to advance SPY072 into late-stage development for hidradenitis suppurativa.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Offering expected to raise approximately $350.0 million in gross proceeds. 4.3% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds use supports Gastroenterology, Rheumatology and Dermatology development, including trials, manufacturing and Phase 3 readiness.
- Minor point. Forward-looking: it has not happened yet and may not happen.New program funding intended to advance SPY072 into late-stage development for hidradenitis suppurativa.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.4,117,648 new common shares at $85.00 each dilute existing holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriters' 30-day option permits up to an additional approximately $52.5 million of common shares, adding potential dilution.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and other offering expenses reduce proceeds available to Spyre.
News Explained
If completed, the priced issuance of 4,117,648 new common shares would increase Spyre’s share count and reduce existing holders’ percentage ownership, absent offsetting changes.
Key Figures
- Shares offered
- 4,117,648 shares
- Common stock public offering
- Public offering price
- $85.00 per share
- Priced offering
- Gross proceeds
- $350.0 million
- Expected before underwriting discounts, commissions, and other offering expenses
- Additional underwriter option
- $52.5 million
- Additional shares under the same terms and conditions
- Option period
- 30 days
- Underwriter option to purchase additional shares
- Expected closing
- October 7, 2026
- Subject to customary closing conditions
Previous Offering Reports
-
Priced 6.5 million shares at $62, with a 30-day option for up to $60.5 million.
-
Priced 14,864,865 shares at $18.50, with a 30-day option for 2,229,729 shares.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
registration statement regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of
Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.
Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.
A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
Safe Harbor / Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company's expectations, or otherwise, except as required by law.
For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
For Media:
Josie Butler, 1AB
josie@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Spyre Therapeutics' public offering expected to close?
Spyre expects the offering to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.